Drug and disease signature integration identifies synergistic combinations in glioblastoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug and disease signature integration identifies synergistic combinations in glioblastoma
Authors
Keywords
-
Journal
Nature Communications
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-12-10
DOI
10.1038/s41467-018-07659-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
- (2018) Zhenyi An et al. ONCOGENE
- Drug Repositioning in Glioblastoma: A Pathway Perspective
- (2018) Sze Kiat Tan et al. Frontiers in Pharmacology
- The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations
- (2018) Alexandra B. Keenan et al. Cell Systems
- Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains
- (2018) Jinhua Wang et al. ACS Chemical Biology
- What are the prospects for combination therapy for glioblastoma?
- (2017) Erin Morgan et al. Expert Review of Neurotherapeutics
- Data Portal for the Library of Integrated Network-based Cellular Signatures (LINCS) program: integrated access to diverse large-scale cellular perturbation response data
- (2017) Amar Koleti et al. NUCLEIC ACIDS RESEARCH
- Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling
- (2017) Mario Niepel et al. Nature Communications
- What are the prospects for combination therapy for glioblastoma?
- (2017) Erin Morgan et al. Expert Review of Neurotherapeutics
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
- (2016) Alison M. Kurimchak et al. Cell Reports
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature
- (2015) Megan O. Jacus et al. CLINICAL PHARMACOKINETICS
- Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
- (2015) Philipp Rathert et al. NATURE
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation
- (2015) Chiara Pastori et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
- (2015) Timothy J. Stuhlmiller et al. Cell Reports
- A Cell Biologist’s Field Guide to Aurora Kinase Inhibitors
- (2015) Christian O. de Groot et al. Frontiers in Oncology
- Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
- (2015) Bhagwan Yadav et al. Computational and Structural Biotechnology Journal
- Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF-MEK-ERK Pathway in Cancer
- (2014) G. L. Johnson et al. CLINICAL CANCER RESEARCH
- Emerging treatment strategies for glioblastoma multiforme
- (2014) S. K. Carlsson et al. EMBO Molecular Medicine
- BET bromodomain proteins are required for glioblastoma cell proliferation
- (2014) Chiara Pastori et al. Epigenetics
- Casein Kinase 1δ-dependent Wee1 Protein Degradation
- (2014) Clara Penas et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
- (2014) Pietro Ciceri et al. Nature Chemical Biology
- TCGA-Assembler: open-source software for retrieving and processing TCGA data
- (2014) Yitan Zhu et al. NATURE METHODS
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
- (2014) A. P. Patel et al. SCIENCE
- The role of laser interstitial thermal therapy in enhancing progression-free survival of difficult-to-access high-grade gliomas: a multicenter study
- (2014) Alireza M. Mohammadi et al. Cancer Medicine
- Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
- (2013) Z. Cheng et al. CLINICAL CANCER RESEARCH
- Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML
- (2013) K R Kampen et al. LEUKEMIA
- The Cancer Genome Atlas Pan-Cancer analysis project
- (2013) John N Weinstein et al. NATURE GENETICS
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
- (2013) Q. T. Ostrom et al. NEURO-ONCOLOGY
- Focused Ultrasound-Induced Blood–Brain Barrier Opening to Enhance Temozolomide Delivery for Glioblastoma Treatment: A Preclinical Study
- (2013) Kuo-Chen Wei et al. PLoS One
- Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
- (2012) J. S. Logue et al. GENES & DEVELOPMENT
- Temozolomide: Mechanisms of Action, Repair and Resistance
- (2011) Jihong Zhang et al. Current Molecular Pharmacology
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase
- (2010) Nicholas D. Adams et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma
- (2009) B. Mukherjee et al. CANCER RESEARCH
- Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer
- (2008) J. Sigmond et al. ANNALS OF ONCOLOGY
- Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
- (2008) Eric Raymond et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now